Supply of the product Dinoprostone (Prostine E2) by Pfizer Australia

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring that these products are safe, of high quality, and effective for their intended use. The Act was introduced to address the need for a comprehensive legal framework governing the importation, manufacture, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood products. The Act was enacted by the Parliament of Australia, aiming to protect public health by regulating the therapeutic goods industry. This legislative action was essential to establish a robust system that would maintain the integrity and safety of therapeutic goods available to the Australian public. The specific consent granted under the Act in this instance was issued by the delegate of the Secretary of the Department of Health to allow the supply of certain batches of dinoprostone vaginal gel that do not fully conform to the stipulated storage conditions and labelling requirements, under specific conditions and for a limited period.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing a broad range of products including medicines, medical devices, blood, and tissues. The Act governs the quality, safety, and efficacy of therapeutic goods, ensuring they meet specific standards before being marketed or supplied within Australia. This legislation applies to all entities and individuals involved in the supply, manufacture, or advertising of therapeutic goods, including pharmaceutical companies, healthcare professionals, and distributors. The Act has a national reach, applying across the Commonwealth, states, and territories of Australia. Certain therapeutic goods and activities, such as the supply of certain low-risk goods or the use of goods for personal or domestic purposes, may be exempt from some provisions of the Act. The Therapeutic Goods Administration (TGA), as the regulatory authority, can extend or restrict the application of the Act through subordinate instruments such as therapeutic goods orders (TGOs), which provide additional detail and specific requirements for different types of therapeutic goods. In the case of the consent given for the supply of dinoprostone (PROSTIN E2) vaginal gel 2 mg, the Act facilitates the controlled distribution of a product that does not conform to specific labelling and storage conditions, subject to conditions that ensure its safe and appropriate use.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) governs the regulation of therapeutic goods in Australia. In this instance, the Act permits the supply of the product dinoprostone (PROSTIN E2) vaginal gel 2 mg by Pfizer Australia Pty Ltd, despite the product not fully complying with certain standards stipulated in Therapeutic Goods Order (TGO) 69 (sections 14 and 14A). Specifically, the product lacks the required signal headings/warning statements and the approved storage condition (subsection 3(2)(j) of TGO 69). This consent is granted under section 15(1) of the Act, but it comes with specific conditions that must be met. The entities involved, particularly Pfizer Australia Pty Ltd, are obligated to ensure that the product is supplied with the correct labels that have the Australian sponsor's name and address, along with the AUST R number, over stickered onto the carton labels of the affected stock. This consent is strictly applicable to certain batches (Z07998, Z08820, and A02878) and is valid until the end of March 2014. The product must be intended for use in Saudi Arabia and the Arabian Gulf countries, and it must be identical to the product already approved in Australia, aside from the labelling differences. Failure to adhere to the conditions specified in this consent could result in serious consequences. Under the Act, breaches of the terms may lead to enforcement actions, including the possibility of fines or other penalties. The maximum penalties for such breaches are not explicitly stated in the document, but they can be severe and are designed to ensure compliance with the therapeutic goods regulations. The Therapeutic Goods Administration (TGA) has the authority to take action against non-compliant entities, which may include recalls, fines, and criminal charges depending on the severity and nature of the breach.